BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 15, Issue 8
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (3936)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.
Item 
Count 
PDF151
HTML1818
Figures (1-1)504
Tables (1-1)484
 Sum=2957
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse202
Download632
 Sum=834
Aug 15, 2024 (publication date) through Nov 28, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial
Copyright ©The Author(s) 2024.
World J Diabetes. Aug 15, 2024; 15(8): 1663-1671
Published online Aug 15, 2024. doi: 10.4239/wjd.v15.i8.1663
Table 1 Medication-related information
Therapeutic drug
Anti-inflammatory properties
Risks
InsulinYesRisk of hypoglycemia
SGLT-2 inhibitorsYesRisk of euglycemic diabetic ketoacidosis
DPP-4 inhibitorsYesRelatively safe
GLP-1 RAYesGastrointestinal symptoms
MetforminYesRisk of lactic acidosis
PioglitazoneYesRisk of fluid retention and heart failure
DPP-4: Dipeptidyl peptidase-4; GLP-1RA: Glucagon-like peptide-1 receptor agonist; SGLT-2: Sodium-glucose cotransporter-2.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345